Universal Peptide Probes for the Multiscale Isolation of Extracellular Vesicles

# Record card
138
Thematic areas
Health & Biotech
Health & Biotech / Smart Devices for Health and Wellness
Health & Biotech / Nanomedicine
Health & Biotech / Diagnostic, Medical imaging & advanced bioimaging
Health & Biotech / Regenerative Medicine
Health & Biotech / Care, Hygiene, Cosmetics
Health & Biotech / Biosensors
Health & Biotech / Micro and nanotechnology related to biological sciences
Health & Biotech / Bio-medicals
Health & Biotech / Diagnostic kits
Chemicals & Physics
Chemicals & Physics / Separation technologies
Description

We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e. the use of peptides sensitive to the curvature of biological membranes (membrane sensing peptides - MSP- ) for the specific and at the same time universal capture (not dependent on surface markers) of all small EVs (50-200nm). MSPs can be produced synthetically, in a scalable way and at low cost, and offer great versatility of integration on analytical supports or purification of different nature.

Business fields
Industry
Type of innovation
Product innovation
Description of innovative features / Competitive advantages

Traditional affinity methods for the isolation of EVs are generally based on the use of antibodies to proteins present on their membrane. However, these markers are not uniformly expressed in the various subpopulations of EVs. As such, they allow a partial and not fully representative recovery of the EVs present in a sample. The technology based on MSPs proposed by us transcends this problem, being the affinity directed towards universal characteristics of the small vesicles (charge and membrane curvature). This determines a high yield and universally representative capture, as well as allowing the isolation of VE of plant and animal species indifferently. The synthetic aspects and prospective scale-up towards the isolation of VE on a large scale are also totally peculiar to these ligands, since antibodies have no application in this sector due to the high costs.

Reference market
Total innovation
Impacts on existing markets
Development stage
Feasibility
TRL
4
5
Advantages
New product/process/service/technology
Cost reduction
Patented technology
Yes
Country/ies

PCT

Technology validation/demonstration
Internal validation
Market positioning
Italian
European
International
Partner required
Enteprise
Seed capital
Cooperation in national /european / international project

Information
For more information and/or to be put in contact with the Research Team, please contact the Project Manager:

Barbara Angelini - Project Manager
CNR - Unità Valorizzazione della Ricerca
Phone number 06.49932415
E-mail barbara.angelini@cnr.it